MaxCyte, Inc. (MXCT:NASDAQ) closed at $1.40 on October 23, 2026, down 2.10% on the day. The stock trades 22.4% below its 52-week high of $1.81 and 117.7% above its 52-week low of $0.643. Over the past year, it lost 14.1%. MaxCyte, Inc. is part of the Consumer Services sector.
In 252 trading sessions since October 23, 2025, MXCT closed higher on 112 days (44%). Its best day was October 14, 2026 (+29.67%) and its worst was November 6, 2025 (-11.98%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 3 times.
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
Find more stocks like MXCT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.